IFM Investors Pty Ltd Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)


Share on StockTwits

IFM Investors Pty Ltd increased its position in Pfizer Inc. (NYSE:PFE) by 16.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 537,381 shares of the biopharmaceutical company’s stock after buying an additional 75,149 shares during the quarter. Pfizer accounts for approximately 0.6% of IFM Investors Pty Ltd’s holdings, making the stock its 29th biggest holding. IFM Investors Pty Ltd’s holdings in Pfizer were worth $19,781,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Northwest Wealth Management LLC increased its stake in shares of Pfizer by 2.4% in the third quarter. Northwest Wealth Management LLC now owns 11,311 shares of the biopharmaceutical company’s stock worth $415,000 after buying an additional 268 shares during the period. HNP Capital LLC increased its position in Pfizer by 1.7% during the 3rd quarter. HNP Capital LLC now owns 16,689 shares of the biopharmaceutical company’s stock valued at $607,000 after purchasing an additional 275 shares during the period. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC increased its position in Pfizer by 2.8% during the 3rd quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC now owns 10,195 shares of the biopharmaceutical company’s stock valued at $374,000 after purchasing an additional 277 shares during the period. Redhawk Wealth Advisors Inc. increased its position in Pfizer by 3.7% during the 3rd quarter. Redhawk Wealth Advisors Inc. now owns 7,710 shares of the biopharmaceutical company’s stock valued at $283,000 after purchasing an additional 278 shares during the period. Finally, Day & Ennis LLC increased its position in Pfizer by 1.2% during the 3rd quarter. Day & Ennis LLC now owns 23,589 shares of the biopharmaceutical company’s stock valued at $866,000 after purchasing an additional 283 shares during the period. 69.08% of the stock is currently owned by institutional investors.

In other Pfizer news, major shareholder Pfizer Inc purchased 1,200,000 shares of Pfizer stock in a transaction dated Tuesday, October 27th. The stock was purchased at an average price of $10.00 per share, with a total value of $12,000,000.00. Following the transaction, the insider now directly owns 27,349,211 shares of the company’s stock, valued at $273,492,110. The purchase was disclosed in a document filed with the SEC, which is available through this link. 0.08% of the stock is owned by corporate insiders.

A number of research analysts have issued reports on the stock. SVB Leerink boosted their price objective on shares of Pfizer from $42.00 to $43.00 and gave the company a “market perform” rating in a research report on Wednesday, October 28th. Atlantic Securities downgraded shares of Pfizer from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $44.00 to $39.00 in a research report on Monday, October 12th. Barclays boosted their target price on shares of Pfizer from $35.00 to $37.00 and gave the company an “equal weight” rating in a report on Friday, December 4th. TheStreet upgraded shares of Pfizer from a “c+” rating to a “b-” rating in a report on Wednesday, November 25th. Finally, Berenberg Bank initiated coverage on shares of Pfizer in a report on Tuesday, September 29th. They set a “hold” rating and a $38.00 target price on the stock. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $39.87.

PFE opened at $36.86 on Thursday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.42. The stock has a market capitalization of $204.88 billion, a P/E ratio of 14.63, a P/E/G ratio of 3.10 and a beta of 0.66. The company’s 50-day simple moving average is $38.25 and its two-hundred day simple moving average is $37.19. Pfizer Inc. has a 52-week low of $27.88 and a 52-week high of $43.08.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.01. The business had revenue of $12.13 billion for the quarter, compared to analysts’ expectations of $12.30 billion. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The business’s revenue for the quarter was down 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 EPS. Research analysts forecast that Pfizer Inc. will post 2.84 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 5th. Stockholders of record on Friday, January 29th will be given a dividend of $0.39 per share. The ex-dividend date is Thursday, January 28th. This represents a $1.56 annualized dividend and a dividend yield of 4.23%. This is a positive change from Pfizer’s previous quarterly dividend of $0.38. Pfizer’s dividend payout ratio is presently 51.53%.

Pfizer Company Profile

Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.

Featured Article: The benefits and drawbacks of dollar cost averaging

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.